SEC-PR-2024-189 (12-03-24) (T) SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews – SEC declines to impose civil penalties against company due to its self-reporting, remediation, and cooperation. (A) SEC-PR-2024-189 (C) SEC-PR-2412 / Disclosure Failures (S) https://www.sec.gov/newsroom/press-releases/2024-189